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The authors wish to make the following corrections to this paper [1]:
On page 26, the sentence, “If the overall test is not significant, then the experimental treatment is
compared to the control treatment in the biomarker-positive patients using the type I error a = 0.05.”
should be “If the overall test is not significant, then the experimental treatment is compared to the
control treatment in the biomarker-positive patients using the significance level 0.05 − a.”
They would also like to remove the last paragraph of page 32 due to inaccurate description of the
adaptive signature design:
“The same analysis plan was used in the adaptive signature design which is further described in
our methodological review regarding the biomarker-guided adaptive designs, Antoniou et al., 2016 [35].
More precisely, the difference between the adaptive signature design and the fall-back design is the
following: in the adaptive signature design, in case that the first stage failures to show treatment
effectiveness in the entire population, then the study population is divided in order to develop and
validate a biomarker, using a split sample strategy, whereas in the biomarker-positive and overall
strategies design with fall-back analysis the biomarker assessment is conducted at the beginning of the
trial. However, both of the designs test at the first stage the entire population at the significance level
a1 and at the second stage the biomarker-positive patients at the significance level a2 = a − a1.”
These changes have no material impact on the conclusions of the paper. The authors would like
to apologize for any inconvenience caused to the readers by these changes.
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